Sodium Oxybate
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Sodium Oxybate: From Narcolepsy with Cataplexy to Insomnia
One-Sentence Summary
Sodium oxybate (Xyrem) is a GABA-B/GHB receptor agonist originally used to treat narcolepsy with cataplexy and excessive daytime sleepiness. The TxGNN model predicts it may also be effective for Insomnia, with 13 clinical trials and 13 publications identified in this evidence pack, though only one completed randomized trial directly targets chronic insomnia.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Narcolepsy with cataplexy and excessive daytime sleepiness (derived from clinical trial background descriptions in this pack; no formal EU authorization record available) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| EU Market Status | Not marketed (per this dataset) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed structured mechanism-of-action data for this drug entry is marked as a data gap, but the evidence pack’s own repurposing rationale provides a usable mechanistic summary: sodium oxybate is a GABA-B and GHB receptor agonist that induces slow-wave sleep (SWS) and consolidates overall sleep architecture. This hypnotic pharmacological property has already been clinically validated in narcolepsy, where it improves nighttime sleep consolidation alongside its approved cataplexy indication.
Narcolepsy and insomnia are mechanistically connected through shared sleep-architecture pathways: narcolepsy patients commonly experience fragmented, disrupted nighttime sleep in addition to daytime symptoms, and sodium oxybate’s core action of deepening slow-wave sleep directly addresses the sleep-initiation and sleep-maintenance difficulties that define insomnia. This link is reflected in a completed Phase 2 head-to-head randomized trial comparing sodium oxybate against zolpidem in patients with chronic insomnia (NCT00383643).
At the same time, sodium oxybate carries a well-recognized high abuse/dependence potential and risk of respiratory depression as a controlled GHB-class compound. Any mechanistic rationale for an insomnia indication must be weighed against this risk profile, which is why the current recommendation remains cautious despite plausible pharmacology.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00383643 | Phase 2 | Completed | 48 | Randomized, double-blind, double-dummy trial comparing sodium oxybate (Xyrem) with zolpidem (Ambien) and placebo for long-term efficacy in chronic insomnia — the most directly relevant trial for this indication |
| NCT02637648 | Phase 3 | Unknown | 60 | Placebo-controlled RCT of oral sodium oxybate (3–9 g/night) for headache prophylaxis and sleep-quality improvement in chronic/episodic cluster headache; sleep endpoints included but primary population is headache, not insomnia |
| NCT00641186 | Phase 2 | Completed | 30 | Open-label trial evaluating sodium oxybate for excessive daytime sleepiness and nocturnal sleep disturbance in mild-to-moderate Parkinson’s disease |
| NCT04803786 | N/A | Completed | 110 | Real-world observational study of narcolepsy patients transitioning from sodium oxybate (Xyrem) to low-sodium oxybate (Xywav), informing dosing and tolerability patterns |
| NCT06421532 | Phase 2 | Enrolling by invitation | 60 | Investigates whether deepening sleep with low-sodium oxybate enhances glymphatic clearance of amyloid-β in cerebral amyloid angiopathy patients |
| NCT07077278 | Phase 4 | Not yet recruiting | 25 | Placebo-controlled, randomized-withdrawal study of low-sodium oxybate for sleep-quality-linked autonomic symptoms in idiopathic hypersomnia with POTS |
| NCT04508166 | N/A | Completed | 27 | Tests whether boosting deep sleep (including via sodium oxybate) after trauma exposure reduces post-traumatic intrusive memories in healthy volunteers |
| NCT01584934 | Phase 4 | Withdrawn | 0 | Planned double-blind, placebo-controlled crossover trial of sodium oxybate for fatigue and sleep quality in chronic fatigue syndrome; withdrawn before enrollment |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40120323 | 2025 | Cohort | J Clin Neurosci | Propensity-matched cohort characterizing comorbidities and treatment patterns of narcolepsy patients treated with immediate-release sodium oxybate |
| 26171909 | 2015 | Review (Cochrane) | Cochrane Database Syst Rev | Systematic review of opioid, hypnotic, and sedating medication effects on sleep-disordered breathing, relevant to sedative-hypnotic safety context |
| 18852348 | 2008 | Open-label pilot | Arch Neurol | Polysomnographic study of sodium oxybate for excessive daytime sleepiness and nocturnal sleep disturbance in Parkinson’s disease |
| 11174231 | 2001 | Case series/Review (safety) | Ann Emerg Med | Describes GHB withdrawal syndrome — key safety consideration for chronic dosing regimens such as those proposed for insomnia |
| 31526967 | 2019 | Case report | Sleep Med | Sodium oxybate used to manage severe sleep deprivation in a child with EBV encephalitis affecting the sleep-wake regulation system |
| 37590830 | 2023 | Review | Continuum (Minneap Minn) | Comprehensive review of pediatric sleep disorders, including insomnia, narcolepsy, and related conditions |
| 18805301 | 2008 | Review | Rev Neurol | Overview of narcolepsy with cataplexy, including sleep-maintenance insomnia as an associated feature |
| 20082966 | 2009 | Review | Parkinsonism Relat Disord | Review of sleepiness and sleep disturbance in Parkinson’s disease, contextualizing sodium oxybate’s use in sleep-wake disorders |
Safety Considerations
Please refer to the SmPC for safety information.
Note: The evidence pack flags a Blocking-severity data gap (DG001) for TFDA label warnings/contraindications, meaning formal safety screening (S1) could not be completed for this candidate. Independently of this gap, sodium oxybate is a controlled substance with well-documented risks of abuse, physical dependence, and respiratory depression, which must be factored into any future indication-expansion assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for insomnia is plausible and is supported by one completed Phase 2 head-to-head RCT against zolpidem (L2 evidence), but a Blocking data gap on official safety labeling prevents the mandatory safety pre-assessment, and this dataset shows zero current EU marketing authorizations for the drug. Given sodium oxybate’s recognized abuse/dependence and respiratory-depression risk, the candidate should not advance until these gaps are closed.
To proceed, the following is needed:
- Official label/SmPC safety data (warnings, contraindications, drug interactions) to resolve the Blocking gap (DG001)
- Confirmed mechanism-of-action documentation from DrugBank (DG002)
- Verification of current EU marketing status for sodium oxybate products (e.g., Xyrem, Xywav)
- Completed relevance grading for the clinical trials and literature currently marked “pending”
- A dedicated abuse/diversion risk assessment given the drug’s controlled-substance status, before any insomnia-indication development plan is drafted
Note on other predicted indications: The remaining nine candidates in this evidence pack (e.g., restless legs syndrome, Wernicke-Korsakoff syndrome, ADHD, cauda equina syndrome) are rated L4–L5 and are largely either adverse-effect signals (RLS, Wernicke-Korsakoff) or unsupported KG-embedding noise with no clinical or literature backing; none are recommended for further evaluation at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.